HiMAL:多模式分层多任务辅助学习框架,用于预测阿尔茨海默病的进展
Sayantan Kumar1,2, Sean C Yu2, Andrew Michelson2,3
1Department of Computer Science and Engineering, McKelvey School of Engineering, Washington University in St. Louis, St. Louis, MO 63130, United States.
JAMIA open
|September 19, 2024
概括
一个新的分层多任务辅助学习 (HiMAL) 框架准确地预测了轻度认知障碍患者阿尔茨海默病的进展. 该工具通过预测六个月前的认知衰退,有助于早期干预.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医疗信息学 医疗信息学
背景情况:
- 轻度认知障碍 (MCI) 是阿尔茨海默病 (AD) 的前身.
- 准确预测MCI到AD过渡对于及时干预至关重要.
- 现有的预测模型往往缺乏多式联运数据集成和纵向分析.
研究的目的:
- 开发和验证一种新的多模式框架,分层多任务辅助学习 (HiMAL),用于预测认知复合函数.
- 为了估计从MCI过渡到AD的纵向风险.
- 为预测疾病进展提供临床信息解释.
主要方法:
- 利用来自阿尔茨海默氏病神经成像计划 (ADNI) 数据集的多模式纵向数据 (成像,认知,临床).
- 开发了HiMAL框架,用于在6个月内预测AD转化.
- 将HiMAL性能与使用AUROC和AUPRC指标的最先进基线进行比较.
- 进行了废弃研究以确定模式贡献,并提供了纵向解释.
主要成果:
- 与单任务,单模式基线 (AUROC=0.923,AUPRC=0.623) 相比,HiMAL表现出优异的预测性能.
- 剥离分析确定成像和认知得分是预测准确性的关键贡献者.
- 该模型成功地以高准确度 (P < .05) 预测了疾病进展.
结论:
- HiMAL框架提供了一种强大而准确的方法来预测MCI到AD的进展.
- 模型解释为认知衰退提供了临床相关的见解.
- 由于HiMAL依赖于EHR数据,这表明对高风险患者的临床监测和管理有很大的转化潜力.
更多相关视频
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
18.9K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.8K
相关概念视频
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
